160 related articles for article (PubMed ID: 27802782)
21. Improvement in soluble expression levels of a diabody by exchanging expression vectors.
Liu F; Chen Z; Jiang W; Yang C; Xiong D; Zhu Z
Protein Expr Purif; 2008 Nov; 62(1):15-20. PubMed ID: 18667166
[TBL] [Abstract][Full Text] [Related]
22. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
23. [In vitro cytolysis of B-lymphoma cells mediated by an anti-CD3/anti-CD20 bispecific single-chain antibody].
Yu R; Li SC; Wu BC; Liu H; Ye LL; Liu XM; Wang QW; Chen ZL
Sheng Wu Gong Cheng Xue Bao; 2006 May; 22(3):384-90. PubMed ID: 16755915
[TBL] [Abstract][Full Text] [Related]
24. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
[TBL] [Abstract][Full Text] [Related]
25. [Expression, identification and bioactivity characterization of an anti-CD3/anti-CD20 bispecific single-chain antibody].
Yu R; Li SC; Wu BC; Liu H; Ye LL; Chen ZL
Sheng Wu Gong Cheng Xue Bao; 2005 Mar; 21(2):289-93. PubMed ID: 16013492
[TBL] [Abstract][Full Text] [Related]
26. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
Foran JM; Norton AJ; Micallef IN; Taussig DC; Amess JA; Rohatiner AZ; Lister TA
Br J Haematol; 2001 Sep; 114(4):881-3. PubMed ID: 11564080
[TBL] [Abstract][Full Text] [Related]
27. Bispecific antibody treatment of murine B cell lymphoma.
De Jonge J; Heirman C; De Veerman M; Van Meirvenne S; Demanet C; Brissinck J; Thielemens K
Cancer Immunol Immunother; 1997; 45(3-4):162-5. PubMed ID: 9435864
[TBL] [Abstract][Full Text] [Related]
28. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
29. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
30. There Are No Magic Bullets in Hematopathology: Even Immunostains for CD20 and CD3 Can Get You Into Trouble.
Ferry JA
Adv Anat Pathol; 2018 Jan; 25(1):14-23. PubMed ID: 28914619
[TBL] [Abstract][Full Text] [Related]
31. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
32. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
[TBL] [Abstract][Full Text] [Related]
33. Bispecific monoclonal antibody therapy of B-cell malignancy.
Weiner GJ; De Gast GC
Leuk Lymphoma; 1995 Jan; 16(3-4):199-207. PubMed ID: 7719227
[TBL] [Abstract][Full Text] [Related]
34. Construction and characterization of a bispecific anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Li B; Zhang X; Shi S; Zhao L; Zhang D; Qian W; Zheng L; Gao J; Wang H; Guo Y
Cancer Res; 2010 Aug; 70(15):6293-302. PubMed ID: 20631068
[TBL] [Abstract][Full Text] [Related]
35. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
36. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
[TBL] [Abstract][Full Text] [Related]
37. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.
Jensen M; Tan G; Forman S; Wu AM; Raubitschek A
Biol Blood Marrow Transplant; 1998; 4(2):75-83. PubMed ID: 9763110
[TBL] [Abstract][Full Text] [Related]
38. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
39. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
